DaVita (NYSE: DVA) recently extended the pilot phase of a previously announced supply and collaboration agreement with Nuwellis (NASDAQ: NUWE) until Aug 31, 2024.At the conclusion of the pilot phase, DaVita may extend the supply agreement with Nuwellis for continued provision of both inpatient and outpatient ultrafiltration services for up to 10 years. The objective of this program is to test Aquadex ultrafiltration therapy in certain U.S. marketplaces for adult patients with congestive heart failure and associated disorders. The extension of the pilot phase will provide DaVita, serving as a leading provider of kidney care services, additional time to evaluate the use of ultrafiltration therapy with the Aquadex SmartFlow system with high-need patients in the hospital. Price Performance In the past six months, DVA shares have gained 33.9% compared with the the industry's rise of 14.9%. The S&P 500 has gained 16% in the same time frame. Image Source: Zacks Investment Research More on the Collaboration In June 2023, DaVita and Nuwellis entered into a supply and collaboration agreement for the use of Aquadex ultrafiltration therapy to treat adult patients with congestive heart ...